Nanowired drug delivery for neuroprotection in central nervous system injuries: Modulation by environmental temperature, intoxication of nanoparticles, and comorbidity factors

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 4, Issue 2, 2012, Pages 184-203

  Sharma, Hari Shanker ^a   Sharma, Aruna ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE COMPOUNDS; BLOOD-BRAIN BARRIER; BRAIN EDEMA; BRAIN PATHOLOGIES; CENTRAL NERVOUS SYSTEMS; CLINICAL PRACTICES; COMORBIDITY; ENCAPSULATED MATERIALS; ENVIRONMENTAL TEMPERATURE; NEURONAL DAMAGE; NEUROPROTECTION; PATHOPHYSIOLOGY; RAT MODEL; SPINAL CORD INJURY; TARGETED DRUG DELIVERY; TIO;

EPIDEMIOLOGY; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; NANOWIRES; TITANIUM DIOXIDE;

DRUG DELIVERY;

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AP 173; AP 364; AP 713; CARBON NANOTUBE; CARISOPRODOL; DENDRIMER; DIAMORPHINE; DIPIVEFRINE; ENALAPRIL; FUMARIC ACID; H 290 51; LEVODOPA; LIPOSOME; LISDEXAMFETAMINE; LOW DENSITY LIPOPROTEIN RECEPTOR; METHYLPREDNISOLONE; MOLSIDOMINE; NANOCAPSULE; NANOPARTICLE; NANOWIRE; PALIPERIDONE; POLYMER; PREDNISONE; PRIMIDONE; PSILOCYBINE; SOLID LIPID NANOPARTICLE; TENOFOVIR DISOPROXIL; TITANIUM DIOXIDE; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BRAIN EDEMA; COGNITIVE DEFECT; COMORBIDITY; CYTOTOXICITY; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXPOSURE; DRUG RELEASE; ENDOCYTOSIS; ENDOTHELIUM CELL; ENVIRONMENTAL TEMPERATURE; HEAT STRESS; HYPERTENSION; HYPERTHERMIA; INTOXICATION; MICELLE; MOTOR PERFORMANCE; NANOEMULSION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SPINAL CORD INJURY; TIGHT JUNCTION; TREATMENT OUTCOME;

ANIMALS; CENTRAL NERVOUS SYSTEM; COMORBIDITY; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOWIRES; NEUROPROTECTIVE AGENTS; TEMPERATURE;

EID: 84857116562     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.172     Document Type: Review

References (120)

1. Sharma HS. Nanoneuroscience: emerging concepts on nanoneurotoxicity and nanoneuroprotection. Nanomedicine (Lond) 2007, 2:753-758.
2. Sharma HS. A special section on nanoneuroscience: nanoneurotoxicity and nanoneuroprotection. J Nanosci Nanotechnol 2009, 9:4992-4995.
3. Sharma HS. Namnoneuropharmacology and Nanoneurotoxicology. Prog Brain Res 2009, 180: 1-250.
4. Sharma HS. Blood-CNS barrier, neurodegeneration and neuroprotection: recent therapeutic advancements and nano-drug delivery. J Neural Transm 2011, 118:3-6.
5. Muldoon LL, Tratnyek PG, Jacobs PM, Doolittle ND, Christoforidis GA, Frank JA, Lindau M, Lockman PR, Manninger SP, Qiang Y, et al. Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood-Brain Barrier Disruption Consortium meeting. AJNR Am J Neuroradiol 2006, 27:715-721.
6. Ellis-Behnke R. Nano neurology and the four P's of central nervous system regeneration: preserve, permit, promote, plasticity. Med Clin North Am 2007, 91:937-962.
7. Brambilla D, Le Droumaguet B, Nicolas J, Hashemi SH, Wu LP, Moghimi SM, Couvreur P, Andrieux K. Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine 2011, 7:521-540.
8. Elder JB, Liu CY, Apuzzo ML. Neurosurgery in the realm of 10(-9), Part 2: applications of nanotechnology to neurosurgery-present and future. Neurosurgery 2008, 62:269-284.
9. Berman SC, Galpoththawela C, Gilad AA, Bulte JW, Walczak P. Long-term MR cell tracking of neural stem cells grafted in immunocompetent versus immunodeficient mice reveals distinct differences in contrast between live and dead cells. Magn Reson Med 2011, 65:564-574. doi:10.1002/mrm.22613.
10. Yadav KS, Chuttani K, Mishra AK, Sawant KK. Effect of size on the biodistribution and blood clearance of etoposide-loaded PLGA nanoparticles. PDA J Pharm Sci Technol 2011, 65:131-139.
11. Sharma HS, Sharma A. Nanoparticles aggravate heat stress induced cognitive deficits, blood-brain barrier disruption, edema formation and brain pathology. Prog Brain Res 2007, 162:245-273.
12. Sharma HS, Sharma A. Nanoneuroprotection and nanoneurotoxicity: recent progress and future perspectives. Nanomedicine (Lond) 2010, 5:533-537.
13. Muresanu DF, Sharma A, Sharma HS. Diabetes aggravates heat stress-induced blood-brain barrier breakdown, reduction in cerebral blood flow, edema formation, and brain pathology: possible neuroprotection with growth hormone. Ann N Y Acad Sci 2010, 1199:15-26.
14. Muresanu DF, Sharma HS. Chronic hypertension aggravates heat stress induced cognitive dysfunction and brain pathology: an experimental study in the rat, using growth hormone therapy for possible neuroprotection. Ann N Y Acad Sci 2007, 1122:1-22.
15. Sharma HS, Patnaik R, Sharma A. Diabetes aggravates nanoparticles induced breakdown of the blood-brain barrier permeability, brain edema formation, alterations in cerebral blood flow and neuronal injury. An experimental study using physiological and morphological investigations in the rat. J Nanosci Nanotechnol 2010, 10:7931-7945 .
16. Sharma HS, Hussain S, Schlager J, Ali SF, Sharma A. Influence of nanoparticles on blood-brain barrier permeability and brain edema formation in rats. Acta Neurochir Suppl 2010, 106:359-364.
17. 2, 40-50 nm) exacerbate pathophysiology of traumatic spinal cord injury and deteriorate functional outcome in the rat. An experimental study using pharmacological and morphological approaches. J Nanosci Nanotechnol 2009, 9:4970-4980.
18. Sharma HS, Westman J. The Blood-Spinal Cord and Brain Barriers in Health and Disease. San Diego: Academic Press; 2004.1-617.
19. Sharma HS. Blood-central nervous system barriers: the gateway to neurodegeneration, neuroprotection and neuroregeneration. In: Lajtha A, Banik N, Ray SK, eds. Handbook of Neurochemistry and Molecular Neurobiology: Brain and Spinal Cord Trauma. New York, Berlin, Heidelberg: Springer Verlag; 2009, 363-457.
20. Sharma HS. Pathophysiology of blood-brain barrier, brain edema and cell injury following hyperthermia: new role of heat shock protein, nitric oxide and carbon monoxide. An experimental study in the rat using light and electron microscopy. Acta Univ Upsaliensis 1999, 830:1-94.
21. Sharma HS, Sharma A. Breakdown of the blood-brain barrier in stress alters cognitive dysfunction and induces brain pathology. New perspective for neuroprotective strategies. In: Ritsner M, ed. Brain Protection in Schizophrenia, Mood and Cognitive Disorders. New York, Berlin: Springer-Verlag; 2010. 243-304. 2010
22. Rapoport SI. Blood-Brain Barrier in Physiology and Medicine. New York: Raven Press; 1976.
23. Bradbury MWB. The Concept of a Blood-Brain Barrier. Chicester, London: John Wiley and Sons; 1979.
24. Sharma HS. New perspectives for the treatment options in spinal cord injury. Expert Opin Pharmacother 2008, 9:2773-2800.
25. Sharma HS. Pathophysiology of blood-spinal cord barrier in traumatic injury and repair. Curr Pharm Des 2005, 11:1353-1389.
26. Fan W, Wu Y, Li XK, Yao N, Li X, Yu YG, Hai L. Design, synthesis and biological evaluation of brain-specific glucosyl thiamine disulfide prodrugs of naproxen. Eur J Med Chem 2011, 46:3651-3661.
27. Ruiz JF, Kedziora K, Windle H, Kelleher DP, Gilmer JF. Investigation into drug release from colon-specific azoreductase-activated steroid prodrugs using in-vitro models. J Pharm Pharmacol 2011, 63:806-816. doi:10.1111/j.2011.01289.x.
28. Huttunen KM, Rautio J. Prodrugs-an efficient way to breach delivery and targeting barriers. Curr Top Med Chem 2011. PMID: 21671868.
29. Huttunen KM, Raunio H, Rautio J. Prodrugs-from serendipity to rational design. Pharmacol Rev 2011, 63:750-771.
30. Reichel V, Mahringer A, Ott M, Reimold I, Fricker G. The ABC of the blood-brain barrier-regulation of drug efflux pumps. Curr Pharm Des 2011, 17:2762-2770.
31. Miller DW, Hinton M, Chen F. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers. Neurourol Urodyn 2011, 30:1633-1638. doi:10.1002/nau.21110.
32. Panagiotou T, Fisher RJ. Enhanced transport capabilities via nanotechnologies: impacting bioefficacy, controlled release strategies, and novel chaperones. J Drug Deliv 2011, 2011:902403.
33. Emerich DF, Orive G. Nanoparticle-based technologies for treating and imaging brain tumors. Curr Cancer Drug Targets 2010. PMID: 21158722.
34. Fernandes C, Soni U, Patravale V. Nano-interventions for neurodegenerative disorders. Pharmacol Res 2010, 62:166-178.
35. Sharma HS, Ali S, Tian ZR, Patnaik R, Patnaik S, Lek P, Sharma A, Lundstedt T. Nano-drug delivery and neuroprotection in spinal cord injury. J Nanosci Nanotechnol 2009, 9:5014-5037.
36. Sharma HS, Ali SF, Dong W, Tian ZR, Patnaik R, Patnaik S, Sharma A, Boman A, Lek P, Seifert E, et al. Drug delivery to the spinal cord tagged with nanowire enhances neuroprotective efficacy and functional recovery following trauma to the rat spinal cord. Ann N Y Acad Sci 2007, 1122:197-218.
37. Sharma HS, Ali SF, Tian ZR, Patnaik R, Patnaik S, Sharma A, Boman A, Lek P, Seifert E, Lundstedt T. Nanowired-drug delivery enhances neuroprotective efficacy of compounds and reduces spinal cord edema formation and improves functional outcome following spinal cord injury in the rat. Acta Neurochir Suppl 2010, 106:343-350.
38. Hock SC, Ying YM, Wah CL. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead. PDA J Pharm Sci Technol 2011, Mar-65:177-195.
39. Chan HK, Kwok PC. Production methods for nanodrug particles using the bottom-up approach. Adv Drug Deliv Rev 2011, 63:406-416. doi:10.1016/j.addr.2011.03.011.
40. Wan WK, Yang L, Padavan DT. Use of degradable and nondegradable nanomaterials for controlled release. Nanomedicine (Lond) 2007, 2:483-509.
41. Tosi G, Fano RA, Bondioli L, Badiali L, Benassi R, Rivasi F, Ruozi B, Forni F, Vandelli MA. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. Nanomedicine (Lond) 2011, 6:423-436.
42. Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA. Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv 2008, 5:155-174.
43. Roman JA, Niedzielko TL, Haddon RC, Parpura V, Floyd CL. Single-walled carbon nanotubes chemically functionalized with polyethylene glycol promote tissue repair in a rat model of spinal cord injury. J Neurotrauma 2011, 28:2349-2362.
44. Malarkey EB, Fisher KA, Bekyarova E, Liu W, Haddon RC, Parpura V. Conductive single-walled carbon nanotube substrates modulate neuronal growth. Nano Lett 2009, 9:264-268.
45. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 2010, 624:25-37.
46. Roger E, Lagarce F, Garcion E, Benoit JP. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release 2009, 140:174-181.
47. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, Alyautdin R, von Briesen H, Begley DJ. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003, 20:409-416.
48. Etame AB, Smith CA, Chan WC, Rutka JT. Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature. Nanomedicine 2011. PMID: 21616168.
49. Wohlfart S, Khalansky AS, Gelperina S, Begley D, Kreuter J. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier. J Control Release 2011, 154:103-107.
50. Li J, Feng L, Fan L, Zha Y, Guo L, Zhang Q, Chen J, Pang Z, Wang Y, Jiang X, et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 2011, 32:4943-4950.
51. Choi HS, Ashitate Y, Lee JH, Kim SH, Matsui A, Insin N, Bawendi MG, Semmler-Behnke M, Frangioni JV, Tsuda A. Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotechnol 2010, 28:1300-1303.
52. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009, 379:146-157.
53. Kanazawa T, Taki H, Tanaka K, Takashima Y, Okada H. Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration. Pharm Res 2011, 28:2130-2139.
54. Wen Z, Yan Z, He R, Pang Z, Guo L, Qian Y, Jiang X, Fang L. Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration. Drug Deliv 2011, 18:555-561.
55. Elder A, Gelein R, Silva V, Feikert T, Opanashuk L, Carter J, Potter R, Maynard A, Ito Y, Finkelstein J, et al. Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ Health Perspect 2006, 114:1172-1178. Erratum in: Environ Health Perspect. 2006, 114:1178.
56. Fischer KE, Nagaraj G, Hugh Daniels R, Li E, Cowles VE, Miller JL, Bunger MD, Desai TA. Hierarchical nanoengineered surfaces for enhanced cytoadhesion and drug delivery. Biomaterials 2011, 32:3499-3506.
57. Xie C, Cui Y. Nanowire platform for mapping neural circuits. Proc Natl Acad Sci U S A 2010, 107: 4489-4490.
58. Fischer KE, Jayagopal A, Nagaraj G, Daniels RH, Li EM, Silvestrini MT, Desai TA. Nanoengineered surfaces enhance drug loading and adhesion. Nano Lett 2011, 11:1076-1081.
59. Kwon NH, Beaux MF 2nd, Ebert C, Wang L, Lassiter BE, Park YH, McIlroy DN, Hovde CJ, Bohach GA. Nanowire-based delivery of Escherichia coli O157 shiga toxin 1 A subunit into human and bovine cells. Nano Lett 2007, 7:2718-2723.
60. An X, Cao C, Yu X. Fabrication of biocompatible Zn-cysteine nanowires and their application in selective fluorescence detection of Cu2+. J Nanosci Nanotechnol 2010, 10:8356-8361.
61. Choi SJ, Oh JM, Choy JH. Safety aspect of inorganic layered nanoparticles: size-dependency in vitro and in vivo. J Nanosci Nanotechnol 2008, 8:5297-5301.
62. Sharma P, Anguita JV, Stolojan V, Henley SJ, Silva SR. The growth of silica and silica-clad nanowires using a solid-state reaction mechanism on Ti, Ni and SiO(2) layers. Nanotechnology 2010, 21:295603.
63. Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 2010, 10:3223-3230.
64. Tian ZR, Voigt JA, Liu J, McKenzie B, Xu H. Large oriented arrays and continuous films of TiO(2)-based nanotubes. J Am Chem Soc 2003, 125:12384-12385.
65. Sharma HS, Ali SF, Tian ZR, Hussain SM, Schlager JJ, Sjöquist PO, Sharma A, Muresanu DF. Chronic treatment with nanoparticles exacerbate hyperthermia induced blood-brain barrier breakdown, cognitive dysfunction and brain pathology in the rat. Neuroprotective effects of nanowired-antioxidant compound H-290/51. J Nanosci Nanotechnol 2009, 9:5073-5090.
66. Sharma HS, Sharma A, Hussain S, Schlager J, Sjöquist PO, Muresanu D. A new antioxidant compound H-290/51 attenuates nanoparticle induced neurotoxicity and enhances neurorepair in hyperthermia. Acta Neurochir Suppl 2010, 106:351-357.
67. Fabian E, Landsiedel R, Ma-Hock L, Wiench K, Wohlleben W, van Ravenzwaay B. Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats. Arch Toxicol 2008, 82:151-157.
68. Sugibayashi K, Todo H, Kimura E. Safety evaluation of titanium dioxide nanoparticles by their absorption and elimination profiles. J Toxicol Sci 2008, 33:293-298. Erratum in: J Toxicol Sci 2008, 33:668-669.
69. Zhang L, Bai R, Li B, Ge C, Du J, Liu Y, Le Guyader L, Zhao Y, Wu Y, He S, et al. Rutile TiO(2) particles exert size and surface coating dependent retention and lesions on the murine brain. Toxicol Lett 2011, 207:73-81.
70. Foltête AS, Masfaraud JF, Bigorgne E, Nahmani J, Chaurand P, Botta C, Labille J, Rose J, Férard JF, Cotelle S. Environmental impact of sunscreen nanomaterials: Ecotoxicity and genotoxicity of altered TiO(2) nanocomposites on Vicia faba. Environ Pollut 2011, 159:2515-2522.
71. 2 nanotubes as solid-phase extraction adsorbent for the determination of polycyclic aromatic hydrocarbons in environmental water samples. J Environ Sci (China) 2011, 23:860-867.
72. Zhang R, Niu Y, Li Y, Zhao C, Song B, Li Y, Zhou Y. Acute toxicity study of the interaction between titanium dioxide nanoparticles and lead acetate in mice. Environ Toxicol Pharmacol 2010, 30:52-60.
73. Sharma HS. Neurotrophic factors in combination: a possible new therapeutic strategy to influence pathophysiology of spinal cord injury and repair mechanisms. Curr Pharm Des 2007, 13:1841-1874.
74. Sharma HS. Pathophysiology of the blood-spinal cord barrier in traumatic injury. In: Sharma HS, Westman J, eds. The Blood-Spinal Cord and Brain Barriers in Health and Disease. San Diego: Elsevier, Academic Press; 2004, 437-518.
75. Stålberg E, Sharma HS, Olsson Y. Spinal Cord Monitoring. Basic Principles, Regeneration, Pathophysiology and Clinical Aspects. Wien, New York: Springer; 1998, 1-527.
76. Sharma HS, Winkler T, Stålberg E, Gordh T, Alm P, Westman J. Topical application of TNF-α antiserum attenuates spinal cord trauma induced edema formation, microvascular permeability disturbances and cell injury in the rat. Acta Neurochir Suppl 2003, 86:407-413.
77. Sharma HS, Lundstedt T, Flärdh M, Westman J, Post C, Skottner A. Low molecular weight compounds with affinity to melanocortin receptors exert neuroprotection in spinal cord injury-an experimental study in the rat. Acta Neurochir Suppl 2003, 86:399-405.
78. Sharma HS. Neurotrophic factors attenuate microvascular permeability disturbances and axonal injury following trauma to the rat spinal cord. Acta Neurochir Suppl 2003, 86:383-388.
79. Winkler T, Sharma HS, Gordh T, Badgaiyan RD, Stålberg E, Westman J. Topical application of dynorphin A (1-17) antiserum attenuates trauma induced alterations in spinal cord evoked potentials, microvascular permeability disturbances, edema formation and cell injury: an experimental study in the rat using electrophysiological and morphological approaches. Amino Acids 2002, 23:273-281.
80. Nyberg F, Sharma HS. Repeated topical application of growth hormone attenuates blood-spinal cord barrier permeability and edema formation following spinal cord injury: an experimental study in the rat using Evans blue, ([125])I-sodium and lanthanum tracers. Amino Acids 2002, 23:231-239.
81. Sharma HS, Westman J, Gordh T, Alm P. Topical application of brain derived neurotrophic factor influences upregulation of constitutive isoform of heme oxygenase in the spinal cord following trauma an experimental study using immunohistochemistry in the rat. Acta Neurochir Suppl 2000, 76:365-369.
82. Sharma HS, Westman J, Nyberg F. Topical application of 5-HT antibodies reduces edema and cell changes following trauma of the rat spinal cord. Acta Neurochir Suppl 1997, 70:155-158.
83. Sharma HS, Nyberg F, Gordh T, Alm P, Westman J. Topical application of insulin like growth factor-1 reduces edema and upregulation of neuronal nitric oxide synthase following trauma to the rat spinal cord. Acta Neurochir Suppl 1997, 70:130-133.
84. Sharma HS, Westman J, Olsson Y, Alm P. Involvement of nitric oxide in acute spinal cord injury: an immunocytochemical study using light and electron microscopy in the rat. Neurosci Res 1996, 24:373-384.
85. Chvatal SA, Kim YT, Bratt-Leal AM, Lee H, Bellamkonda RV. Spatial distribution and acute anti-inflammatory effects of Methylprednisolone after sustained local delivery to the contused spinal cord. Biomaterials 2008, 29:1967-1975.
86. Sharma HS. Early microvascular reactions and blood-spinal cord barrier disruption are instrumental in pathophysiology of spinal cord injury and repair: novel therapeutic strategies including nanowired drug delivery to enhance neuroprotection. J Neural Transm 2011, 118:155-176.
87. Sharma HS. Neurobiology of hypertehrmia. Prog Brain Res 2007, 162:1-637.
88. Sharma HS, Westman J. Brain function in hot environment. Prog Brain Res 1998, 115:1-615.
89. Sharma HS. Hyperthermia influences excitatory and inhibitory amino acid neurotransmitters in the central nervous system. An experimental study in the rat using behavioural, biochemical, pharmacological, and morphological approaches. J Neural Transm 2006, 113:497-519.
90. Sharma HS. Methods to produce hyperthermia-induced brain dysfunction. Prog Brain Res 2007, 162:173-199.
91. Sharma HS, Dey PK. Influence of long-term acute heat exposure on regional blood-brain barrier permeability, cerebral blood flow and 5-HT level in conscious normotensive young rats. Brain Res 1987424:153-162.
92. Sharma HS, Dey PK. Probable involvement of 5-hydroxytryptamine in increased permeability of blood-brain barrier under heat stress in young rats. Neuropharmacology 1986, 25:161-167.
93. Sharma HS, Dey PK. Role of 5-HT on increased permeability of blood-brain barrier under heat stress. Indian J Physiol Pharmacol 1984, 28:259-267.
94. Sharma HS, Cervós-Navarro J. Brain oedema and cellular changes induced by acute heat stress in young rats. Acta Neurochir Suppl (Wien) 1990, 51:383-386.
95. Sharma HS, Cervós-Navarro J, Dey PK. Acute heat exposure causes cellular alteration in cerebral cortex of young rats. Neuroreport 1991, 2:155-158.
96. Sharma HS, Westman J, Cervós-Navarro J, Nyberg F. Role of neurochemicals in brain edema and cell changes following hyperthermic brain injury in the rat. Acta Neurochir Suppl 1997, 70:269-274.
97. Sharma HS, Muresanu DF, Sharma A, Patnaik R, Lafuente JV. Chapter 9-Nanoparticles influence pathophysiology of spinal cord injury and repair. Prog Brain Res 2009, 180:154-180.
98. Sharma HS, Ali SF, Hussain SM, Schlager JJ, Sharma A. Influence of engineered nanoparticles from metals on the blood-brain barrier permeability, cerebral blood flow, brain edema and neurotoxicity. An experimental study in the rat and mice using biochemical and morphological approaches. J Nanosci Nanotechnol 2009, 9:5055-5072.
99. Møller P, Jacobsen NR, Folkmann JK, Danielsen PH, Mikkelsen L, Hemmingsen JG, Vesterdal LK, Forchhammer L, Wallin H, Loft S. Role of oxidative damage in toxicity of particulates. Free Radic Res 2010, 44:1-46.
100. Li N, Xia T, Nel AE. The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles. Free Radic Biol Med 2008, 44:1689-1699.
101. Chang CK, Chang CP, Liu SY, Lin MT. Oxidative stress and ischemic injuries in heat stroke. Prog Brain Res 2007, 162:525-546.
102. Yang CY, Lin MT. Oxidative stress in rats with heatstroke-induced cerebral ischemia. Stroke 2002, 33:790-794.
103. Shinohara N, Matsumoto T. Gamo M, Miyauchi A, Endo S, Yonezawa Y, Nakanishi J. Is lipid peroxidation induced by the aqueous suspension of fullerene C60 nanoparticles in the brains of Cyprinus carpio? Environ Sci Technol 2009, 43:948-953.
104. Oberdörster E. Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ Health Perspect 2004, 112:1058-1062.
105. Sharma HS, Sjöquist PO, Ali SF. Drugs of abuse-induced hyperthermia, blood-brain barrier dysfunction and neurotoxicity: neuroprotective effects of a new antioxidant compound H-290/51. Curr Pharm Des 2007, 13:1903-1923.
106. Alm P, Sharma HS, Sjöquist PO, Westman J. A new antioxidant compound H-290/51 attenuates nitric oxide synthase and heme oxygenase expression following hyperthermic brain injury. An experimental study using immunohistochemistry in the rat. Amino Acids 2000, 19:383-394.
107. Sharma HS, Westman J, Nyberg F. Pathophysiology of brain edema and cell changes following hyperthermic brain injury. Prog Brain Res 1998, 115:351-412.
108. Sharma HS, Alm P, Westman J. Nitric oxide and carbon monoxide in the brain pathology of heat stress. Prog Brain Res 1998, 115:297-333.
109. Sharma HS, Sjöquist PO, Ali SF. Alterations in blood-brain barrier function and brain pathology by morphine in the rat. Neuroprotective effects of antioxidant H-290/51. Acta Neurochir Suppl 2010, 106:61-66.
110. Sharma HS, Westman J, Alm P, Sjöquist PO, Cervós-Navarro J, Nyberg F. Involvement of nitric oxide in the pathophysiology of acute heat stress in the rat. Influence of a new antioxidant compound H-290/51. Ann N Y Acad Sci 1997, 813:581-590.
111. Yard EE, Gilchrist J, Haileyesus T, Murphy M, Collins C, McIlvain N, Comstock RD. Heat illness among high school athletes-United States, 2005-2009. J Safety Res 2010, 41:471-474.
112. Nelson NG, Collins CL, Comstock RD, McKenzie LB. Exertional heat-related injuries treated in emergency departments in the U.S., 1997-2006. Am J Prev Med 2011, 40:54-60.
113. Westphal SA, Childs RD, Seifert KM, Boyle ME, Fowke M, Iñiguez P, Cook CB. Managing diabetes in the heat: potential issues and concerns. Endocr Pract 2010, 16:506-511.
114. Cerutti B, Tereanu C, Domenighetti G, Cantoni E, Gaia M, Bolgiani I, Lazzaro M, Cassis I. Temperature related mortality and ambulance service interventions during the heat waves of 2003 in Ticino (Switzerland). Soz Praventivmed 2006, 51:185-193.
115. Ford ES. Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States. Circulation 2011, 123:1737-1744.
116. Forlenza GP, Rewers M. The epidemic of type 1 diabetes: what is it telling us? Curr Opin Endocrinol Diabetes Obes 2011, 18:248-251.
117. Perez L, Tobias A, Querol X, Künzli N, Pey J, Alastuey A, Viana M, Valero N, González-Cabré M, Sunyer J. Coarse particles from Saharan dust and daily mortality. Epidemiology 2008, 19:800-807.
118. Menon PK. Effects of Cerebrolysin, a mixture of neurotrophins on spinal cord injury in relation to nanoparticles treatment. Master's Thesis, Uppsala, Sweden: Uppsala University, Biotechnology Program, (Supervisor: Hari S Sharma), 1-28.
119. Sharma HS, Muresanu DF, Patnaik R, Dora SA, Vitalie V, Laura PD, Alexander B, Buzoianu A, Opincariu I, Menon PK, et al. Superior neuroprotective effects of cerebrolysin in heat stroke following chronic intoxication of Cu or Ag engineered nanoparticles. A comparative study with other neuroprotective agents using biochemical and morphological approaches. J Nanaosci Nanotech 2011, 11:1-21.
120. Sharma HS, Hoopes PJ. Hyperthermia induced pathophysiology of the central nervous system. Int J Hyperthermia 2003, 19:325-354.